<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="Activity\PMC7411463\results\search\disease\results.xml">
  <result pre="major public issue as current hepatobiliary diseases such as nonalcoholic" exact="fatty liver disease," post="drug-induced liver injury, hepatocellular carcinoma, and gallbladder, and biliary"/>
  <result pre="public issue as current hepatobiliary diseases such as nonalcoholic fatty" exact="liver disease," post="drug-induced liver injury, hepatocellular carcinoma, and gallbladder, and biliary"/>
  <result pre="diseases such as nonalcoholic fatty liver disease, drug-induced liver injury," exact="hepatocellular carcinoma," post="and gallbladder, and biliary tract cancers are closely related"/>
  <result pre="antifibrotic, and antitumor activities which contribute to the treatment of" exact="viral hepatitis," post="stone, fibrosis, nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC),"/>
  <result pre="treatment of viral hepatitis, stone, fibrosis, nonalcoholic steatohepatitis (NASH), primary" exact="sclerosing cholangitis" post="(PSC), HCC, cholangiocarcinoma, etc. [8]. Due to the low"/>
  <result pre="of viral hepatitis, stone, fibrosis, nonalcoholic steatohepatitis (NASH), primary sclerosing" exact="cholangitis" post="(PSC), HCC, cholangiocarcinoma, etc. [8]. Due to the low"/>
  <result pre="of disorders characterized by stages of progression from steatosis and" exact="hepatitis" post="to cirrhosis and cancer. This diverse spectrum of hepatic"/>
  <result pre="characterized by stages of progression from steatosis and hepatitis to" exact="cirrhosis" post="and cancer. This diverse spectrum of hepatic diseases is"/>
  <result pre="reported to be more closely associated with metabolic syndromes than" exact="obesity" post="[53]. The antisteatotic effects of C. longa were investigated"/>
  <result pre="decreased the regions of aortic fatty streak in rabbits with" exact="atherosclerosis" post="[58]. The modulatory effects of C. longa against serum"/>
  <result pre="inflammation is crucial in the treatment of hepatobiliary diseases because" exact="hepatitis" post="can be regarded as a stage prior to the"/>
  <result pre="be regarded as a stage prior to the development of" exact="cirrhosis" post="or cancer [60, 61]. The anti-inflammatory effects of C."/>
  <result pre="as a stage prior to the development of cirrhosis or" exact="cancer" post="[60, 61]. The anti-inflammatory effects of C. longa were"/>
  <result pre="in the development of alcoholic or nonalcoholic fatty liver into" exact="cirrhosis" post="or cancer [62]. C. longa improved the major hallmark"/>
  <result pre="development of alcoholic or nonalcoholic fatty liver into cirrhosis or" exact="cancer" post="[62]. C. longa improved the major hallmark of the"/>
  <result pre="intrahepatic MDA levels by increasing antioxidant enzymes, resulting in the" exact="suppression" post="of TNF-Î± activity in the liver of male SD"/>
  <result pre="of intrahepatic MDA and serum TNF-Î± in a TAA-induced liver" exact="cirrhosis" post="model [28]. Therefore, C. longa might exhibit strong anti-inflammatory"/>
  <result pre="its efficacy should be investigated in experimental models that mimic" exact="cholangitis" post="or cholecystitis because curcumin alleviated sclerosing cholangitis in mice"/>
  <result pre="should be investigated in experimental models that mimic cholangitis or" exact="cholecystitis" post="because curcumin alleviated sclerosing cholangitis in mice [63]. 2.5."/>
  <result pre="experimental models that mimic cholangitis or cholecystitis because curcumin alleviated" exact="sclerosing cholangitis" post="in mice [63]. 2.5. Antifibrotic Effect Fibrosis involves excess"/>
  <result pre="models that mimic cholangitis or cholecystitis because curcumin alleviated sclerosing" exact="cholangitis" post="in mice [63]. 2.5. Antifibrotic Effect Fibrosis involves excess"/>
  <result pre="reduced liver function, hepatocyte necrosis, decreased intrahepatic microcirculation, and even" exact="cirrhosis" post="or cancer [64]. However, because fibrosis can be reversed"/>
  <result pre="function, hepatocyte necrosis, decreased intrahepatic microcirculation, and even cirrhosis or" exact="cancer" post="[64]. However, because fibrosis can be reversed unlike liver"/>
  <result pre="hepatic stellate cells (HSCs) contributing to the progression of liver" exact="cirrhosis" post="[39]. The antifibrotic activities of C. longa may be"/>
  <result pre="SD rats [28]. The effects of C. longa against liver" exact="cirrhosis" post="and its complications, such as delayed coagulation, should be"/>
  <result pre="coagulation, should be investigated in further research. Regarding TGF-Î² signaling" exact="suppression" post="and proapoptosis of C. longa against hepatic fibrogenesis, PPAR-Î³"/>
  <result pre="suppressing the hepatic expression of p53 and Bcl-2 and prevented" exact="cancer" post="metastasis by disturbing hepatic MMP activity [45]. With regard"/>
  <result pre="anticancer activities can be applied to treat both HCC and" exact="bile duct cancer." post="Additionally, unlike conventional anticancer drugs, C. longa may have"/>
  <result pre="[68]. Although antibiotics/antivirals and immunosuppressants are used to treat infectious" exact="cholestasis" post="and autoimmune cholestasis, respectively, ursodeoxycholic acid (UDCA) is currently"/>
  <result pre="bile flow [69]. However, the development of drugs to treat" exact="cholestasis" post="and prevent its complications is urgently required as the"/>
  <result pre="models induced by bile duct ligation or related to liver" exact="cirrhosis" post="for evaluating the efficacy of C. longa. Therefore, different"/>
  <result pre="exerted beneficial activities against various types of tumor, such as" exact="lung cancer," post="breast cancer, prostate cancer, cervical cancer, gastric cancer, and"/>
  <result pre="activities against various types of tumor, such as lung cancer," exact="breast cancer," post="prostate cancer, cervical cancer, gastric cancer, and sarcoma cancer"/>
  <result pre="various types of tumor, such as lung cancer, breast cancer," exact="prostate cancer," post="cervical cancer, gastric cancer, and sarcoma cancer [75]. Similarly,"/>
  <result pre="of tumor, such as lung cancer, breast cancer, prostate cancer," exact="cervical cancer," post="gastric cancer, and sarcoma cancer [75]. Similarly, most experimental"/>
  <result pre="cancer, breast cancer, prostate cancer, cervical cancer, gastric cancer, and" exact="sarcoma" post="cancer [75]. Similarly, most experimental studies of Î²-elemene targeting"/>
  <result pre="breast cancer, prostate cancer, cervical cancer, gastric cancer, and sarcoma" exact="cancer" post="[75]. Similarly, most experimental studies of Î²-elemene targeting hepatobiliary"/>
  <result pre="mechanisms of its anticancer effects, Î²-elemene inhibited the proliferation of" exact="cancer" post="cells by increasing histone H1 protein in H22 cells"/>
  <result pre="possess hepatoprotective effects but also anticancer effects. Future research on" exact="biliary tract cancer" post="and liver cancer must be conducted to identify its"/>
  <result pre="effects but also anticancer effects. Future research on biliary tract" exact="cancer" post="and liver cancer must be conducted to identify its"/>
  <result pre="also anticancer effects. Future research on biliary tract cancer and" exact="liver cancer" post="must be conducted to identify its high potency against"/>
  <result pre="anticancer effects. Future research on biliary tract cancer and liver" exact="cancer" post="must be conducted to identify its high potency against"/>
  <result pre="cancer must be conducted to identify its high potency against" exact="cancer" post="with minor impacts on normal cells. 3.3. Ar-Turmerone Aromatic"/>
  <result pre="hepatobiliary system. Furthermore, it could markedly suppress fibrosis, tumorigenesis, and" exact="cholestasis" post="by inhibiting TGF-Î² signaling, the NF-ÎºB pathway, and CYP7A1"/>
  <result pre="as therapeutic candidates for the treatment of toxic hepatitis, alcoholic" exact="liver disease," post="nonalcoholic fatty liver disease, cirrhosis, liver cancer, and cholestatic"/>
  <result pre="for the treatment of toxic hepatitis, alcoholic liver disease, nonalcoholic" exact="fatty liver disease," post="cirrhosis, liver cancer, and cholestatic liver diseases. Regarding the"/>
  <result pre="the treatment of toxic hepatitis, alcoholic liver disease, nonalcoholic fatty" exact="liver disease," post="cirrhosis, liver cancer, and cholestatic liver diseases. Regarding the"/>
  <result pre="toxic hepatitis, alcoholic liver disease, nonalcoholic fatty liver disease, cirrhosis," exact="liver cancer," post="and cholestatic liver diseases. Regarding the molecular mechanism of"/>
  <result pre="carcinoma?Journal of Hepatology201257245345410.1016/j.jhep.2012.03.00422425699 4MoonA. M.SingalA. G.TapperE. B.Contemporary epidemiology of chronic" exact="liver disease" post="and cirrhosisClinical Gastroenterology and Hepatology2019In press10.1016/j.cgh.2019.07.060 5StickelF.SchuppanD.Herbal medicine in"/>
  <result pre="44VidelaL. A.RodrigoR.OrellanaM.et al.Oxidative stress-related parameters in the liver of non-alcoholic" exact="fatty liver disease" post="patientsClinical Science2004106326126810.1042/cs2003028514556645 45Khuda-BukhshA. R.BanerjeeA.BiswasR.PathakS.BoujedainiN.BelonP.Crude extract of turmeric reduces hepato-toxicity"/>
  <result pre="A.RodrigoR.OrellanaM.et al.Oxidative stress-related parameters in the liver of non-alcoholic fatty" exact="liver disease" post="patientsClinical Science2004106326126810.1042/cs2003028514556645 45Khuda-BukhshA. R.BanerjeeA.BiswasR.PathakS.BoujedainiN.BelonP.Crude extract of turmeric reduces hepato-toxicity"/>
  <result pre="the centre of the triangleJournal of Hepatology200848238038110.1016/j.jhep.2007.11.00718093689 63BaghdasaryanA.ClaudelT.KostersA.et al.Curcumin improves" exact="sclerosing cholangitis" post="in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response"/>
  <result pre="centre of the triangleJournal of Hepatology200848238038110.1016/j.jhep.2007.11.00718093689 63BaghdasaryanA.ClaudelT.KostersA.et al.Curcumin improves sclerosing" exact="cholangitis" post="in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response"/>
  <result pre="of human hepatoma cell line (HepG2)Acta Pharmaceutica201666338739810.1515/acph-2016-002827383887 67LeelawatS.LeelawatK.Molecular mechanisms of" exact="cholangiocarcinoma" post="cell inhibition by medicinal plantsOncology Letters201713296196610.3892/ol.2016.548828356985 68SantiagoP.ScheinbergA. R.LevyC.Cholestatic liver"/>
  <result pre="L.)Pharmaceutical Crops201151285410.2174/2210290601102010028 74NairA.AmalrajA.JacobJ.KunnumakkaraA. B.GopiS.Non-curcuminoids from turmeric and their potential in" exact="cancer" post="therapy and anticancer drug delivery formulationsBiomolecules20199113610.3390/biom9010013 75DaiZ. J.TangW.LuW. F.et"/>
  <result pre="H22 ascites hepatoma cell lineMolecular Medicine Reports20126118519022552783 77LiX.LinZ.ZhangB.et al.Î²-elemene sensitizes" exact="hepatocellular carcinoma" post="cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper"/>
  <result pre="through reactive oxygen species-triggered intrinsic and extrinsic pathways in human" exact="hepatocellular carcinoma" post="HepG2 cellsJournal of Agricultural and Food Chemistry201260389620963010.1021/jf301882b22946656 86YueG. G.ChanB."/>
  <result pre="elemene, its main active ingredient β-elemene, and its derivatives in" exact="cancer" post="therapyInternational Journal of Nanomedicine2018136279629610.2147/ijn.s17452730349250 Figure 1 Four noncurcuminoid compounds"/>
 </snippets>
</snippetsTree>
